Key Finding: PepGen Inc. (NASDAQ: PEPG) is a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide (EDO) therapies primarily for myotonic dystrophy type 1 (DM1), with encouraging early Phase 2 data but ongoing financial losses and high stock volatility typical of pre-commercial biotechs.
Fact: PepGen Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on developing oligonucleotide therapeutics for severe neuromuscular and neurological diseases using its proprietary EDO platform, which leverages cell-penetrating peptides for improved delivery to tissues like muscle and the central nervous system.
Interpretation: The EDO platform's preclinical and early clinical data suggest potential for better tissue penetration compared to traditional oligonucleotides, which could address unmet needs in rare genetic diseases.
Uncertainty: Clinical success in later trials is not guaranteed; regulatory hurdles (e.g., past FDA holds) and competition in the DM1 space remain risks.
Limitation/Assumption: Historical details primarily sourced from company disclosures and secondary reports; exact founding team or initial funding rounds not detailed in public summaries.
Interpretation: Positive early data has supported analyst optimism and occasional stock rallies, though volatility persists.
Fact (as of ~July 9–10, 2026 data): Price around $2.00–$2.30 (intraday swings noted); 52-week range $1.01–$7.80; market cap ~$140–160 million; average volume ~850k shares; beta ~1.88; EPS (TTM) -$1.46; no dividends.
| Metric | Value |
|---|---|
| Recent Close | ~$2.30 (+15.58% on sample day) |
| YTD Return | ~64.67% |
| 1-Year Return | ~94.92% |
| Market Cap | ~$140–160M |
| Cash (mrq) | $132.3M |
Uncertainty: Returns are highly variable due to binary clinical events; past performance (e.g., post-IPO decline from $15 range) does not predict future results.
Limitation: Stock data is time-sensitive and reflects snapshots from July 2026; real-time prices, volumes, and analyst targets fluctuate. No forward-looking guarantees.
All information compiled from public web sources as of July 2026. This is not investment advice; consult financial professionals. Data limitations include reliance on third-party reports, potential delays in updates, and inherent uncertainties in biotech clinical development.